drugset

drugset / Trial / NCT00236431

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

NCT00236431 ↗

Phase 3 Completed 1063 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.

Timeline

Start: 2001-05
Primary completion: —
Completion: 2003-12

Publications

Lim AWY, Schneider L, Loy C. Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galantamine	Small molecule	12 mg	Oral

Indications